Omega Therapeutics advances epigenomic programming platform

By The Science Advisory Board staff writers

July 29, 2020 -- Omega Therapeutics has received $85 million in financing to support clinical trials of its epigenomic controllers for programs in oncology, inflammation, autoimmune, metabolic, and rare genetic diseases.

The company's epigenomic programming platform selectively directs the human genome to treat and cure disease by precisely controlling genomic expression without altering native nucleic acid sequences. The platform modulates insulated genomic domains to up- or down-regulate single or multiple genes simultaneously.

The company calls the genomic modulators "epigenomic controllers," and said they are engineered to precisely tune genomic activity with high target specificity and durability. They are composed of a DNA-binding domain and an epigenetic effector domain delivered as messenger RNA which modulate gene expression, according to the firm.

Tessera introduces new genome engineering strategy
Flagship Pioneering, a life science venture capital firm, has introduced Tessera Therapeutics -- a new biotechnology company that will use its Gene Writing...
Horizon Discovery accelerates CRISPR gene editing workflows
Horizon Discovery Group has introduced a new stably expressing Cas9 cell line for knockout experiments and a dCas9-VPR cell line for gene activation experiments.
MaxCyte launches Expert cell engineering products
Cell-based medicines and life sciences company MaxCyte has launched a new line of disposable cell engineering products.

Copyright © 2020

Glasgow International Health Festival
August 24-27
Glasgow, Glasgow City United Kingdom
Pharma Competitive Intelligence Conference and Exhibition
September 21-22
Newark, New Jersey United States
BioProcess International (BPI) Conference
September 27-30
Boston, Massachusetts United States
Laboratory Products Association Annual Meeting
October 1-4
Scottsdale, Arizona United States
Science Advisory Board on LinkedIn
Science Advisory Board on Facebook
Science Advisory Board on Twitter